Innovent's Byvasda (Bevacizumab Biosimilar) Receive NMPA's Approval for Adult Recurrent Glioblastoma
Shots:
- The NMPA has approved Byvasda for the treatment of adult recurrent Glioblastoma which is the third approved indication of Byvasda in China
- The launch of Byvasda has provided Chinese patients with high quality and relatively more affordable bevacizumab biosimilar injection
- Byvasda is a bevacizumab biosimilar and a recombinant humanized anti-VEGF monoclonal antibody drug. Byvasda has been approved in China for the treatment of NSCLC and mCRC
Ref: Innovent | Image: Innovent
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com